Prime Medicine, Inc. stock is traded under the ticker #PRME. Below you can review Prime Medicine, Inc. stock performance in the past 12 months up to August 2026

Total visits to Prime Medicine, Inc.'s top domains

Understand Prime Medicine, Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

primemedicine.com16K

See more with Sales Intelligence

Avg. visit duration in Prime Medicine, Inc.'s top domains

Analyze Prime Medicine, Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

primemedicine.com00:00:48

See more with Sales Intelligence

Avg. pageviews on Prime Medicine, Inc.'s top domains

See how Prime Medicine, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

primemedicine.com1.86

See more with Sales Intelligence

Prime Medicine, Inc. top competitors by domain

Top similar sites in August 2026, ranked by their affinity

sana.comCompany NameSana Biotechnology, Inc.Employees201 - 500HQUnited States, Washington, SeattleAnnual revenue$100M - $200MTotal visits22.6KComputers Electronics and Technology > Graphics Multimedia and Web Design

Top technologies used by Prime Medicine, Inc.

These are the website technologies, by industry, used by Prime Medicine, Inc. top domains

Content Management System (3)

WordPress

Advertising (2)

DoubleClick

Conversion & Analytics (2)

Google Analytics

Email Services (2)

GoDaddy Email

More Technologies

7

See all

News & Signals from Prime Medicine, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsPrime Medicine, Inc. is developing PM647 for alpha-1 antitrypsin deficiency on Jul 8th '26.Beam Therapeutics tumbled nearly 9% following the July 8 arbitration ruling that awarded rival Prime Medicine the right to develop PM647 for alpha-1 antitrypsin deficiency - injecting competitive uncertainty into the BEAM-302 AATD program just as the stock had recently touched a 52-week high near $38.

NewsPrime Medicine, Inc. attended event Goldman Sachs 47th Annual Global Healthcare Conference on Jun 10th '26.CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) - Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 10:40 a.m. ET in Miami Beach, FL.

NewsPrime Medicine, Inc. attended event 2026 ASGCT Annual Meeting on May 11th '26.Prime Medicine will be speaking about their collaboration with Benchling at the 2026 ASGCT Annual Meeting, Monday May 11th, as part of the Automation in CGT Manufacturing workshop.